Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)
China
· Delayed Price · Currency is CNY 9.64
-0.54 (-5.30%)
Apr 29, 2026, 3:00 PM CST
SHA:603229 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 792.76 | 795.07 | 814.85 | 764.23 | 568.89 | Upgrade
|
| Other Revenue | - | 0.22 | 1.92 | 0.32 | 0.81 | Upgrade
|
| Revenue | 792.76 | 795.29 | 816.77 | 764.55 | 569.7 | Upgrade
|
| Revenue Growth (YoY) | -0.32% | -2.63% | 6.83% | 34.20% | 39.21% | Upgrade
|
| Cost of Revenue | 368.56 | 373.39 | 372.41 | 372.58 | 261.29 | Upgrade
|
| Gross Profit | 424.2 | 421.9 | 444.36 | 391.96 | 308.41 | Upgrade
|
| Selling, General & Admin | 117.98 | 123.21 | 118.41 | 114.55 | 81.25 | Upgrade
|
| Research & Development | 167.89 | 100.42 | 78.06 | 67.07 | 68.82 | Upgrade
|
| Other Operating Expenses | -0.3 | 6.54 | 3.32 | 1.97 | 4.64 | Upgrade
|
| Operating Expenses | 285.57 | 236.19 | 199.81 | 186.76 | 156.21 | Upgrade
|
| Operating Income | 138.63 | 185.71 | 244.54 | 205.2 | 152.2 | Upgrade
|
| Interest Expense | - | -7.76 | -7.99 | -6.11 | -1.47 | Upgrade
|
| Interest & Investment Income | 22.28 | 43.08 | 35.75 | 9.6 | 5.78 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 11.4 | 11.37 | 40.58 | -9.67 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.93 | -1.5 | -0.6 | -0.44 | -0.44 | Upgrade
|
| EBT Excluding Unusual Items | 157.98 | 230.92 | 283.07 | 248.84 | 146.41 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.49 | 5.5 | -4.49 | 4.95 | 11.66 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.52 | Upgrade
|
| Asset Writedown | -19.58 | -0.15 | -0.37 | -1.58 | - | Upgrade
|
| Other Unusual Items | - | 3.93 | 12.55 | 3.66 | 1.84 | Upgrade
|
| Pretax Income | 137.9 | 240.2 | 290.76 | 255.86 | 159.39 | Upgrade
|
| Income Tax Expense | 7.33 | 33.41 | 36.86 | 20.48 | 13.46 | Upgrade
|
| Net Income | 130.57 | 206.79 | 253.9 | 235.38 | 145.93 | Upgrade
|
| Net Income to Common | 130.57 | 206.79 | 253.9 | 235.38 | 145.93 | Upgrade
|
| Net Income Growth | -36.86% | -18.55% | 7.87% | 61.29% | 68.05% | Upgrade
|
| Shares Outstanding (Basic) | 816 | 827 | 819 | 804 | 794 | Upgrade
|
| Shares Outstanding (Diluted) | 816 | 827 | 819 | 804 | 794 | Upgrade
|
| Shares Change (YoY) | -1.34% | 0.99% | 1.92% | 1.16% | 6.67% | Upgrade
|
| EPS (Basic) | 0.16 | 0.25 | 0.31 | 0.29 | 0.18 | Upgrade
|
| EPS (Diluted) | 0.16 | 0.25 | 0.31 | 0.29 | 0.18 | Upgrade
|
| EPS Growth | -36.00% | -19.36% | 5.84% | 59.45% | 57.55% | Upgrade
|
| Free Cash Flow | 52.06 | 66.62 | 58.38 | -151.35 | -136.95 | Upgrade
|
| Free Cash Flow Per Share | 0.06 | 0.08 | 0.07 | -0.19 | -0.17 | Upgrade
|
| Dividend Per Share | - | 0.100 | 0.092 | 0.057 | 0.037 | Upgrade
|
| Dividend Growth | - | 8.58% | 61.30% | 53.91% | 62.72% | Upgrade
|
| Gross Margin | 53.51% | 53.05% | 54.40% | 51.27% | 54.14% | Upgrade
|
| Operating Margin | 17.49% | 23.35% | 29.94% | 26.84% | 26.72% | Upgrade
|
| Profit Margin | 16.47% | 26.00% | 31.09% | 30.79% | 25.61% | Upgrade
|
| Free Cash Flow Margin | 6.57% | 8.38% | 7.15% | -19.80% | -24.04% | Upgrade
|
| EBITDA | 212.81 | 248.24 | 285.14 | 239.68 | 182.22 | Upgrade
|
| EBITDA Margin | 26.85% | 31.21% | 34.91% | 31.35% | 31.99% | Upgrade
|
| D&A For EBITDA | 74.19 | 62.53 | 40.59 | 34.48 | 30.02 | Upgrade
|
| EBIT | 138.63 | 185.71 | 244.54 | 205.2 | 152.2 | Upgrade
|
| EBIT Margin | 17.49% | 23.35% | 29.94% | 26.84% | 26.71% | Upgrade
|
| Effective Tax Rate | 5.32% | 13.91% | 12.68% | 8.01% | 8.45% | Upgrade
|
| Revenue as Reported | - | 795.29 | 816.77 | 764.55 | 569.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.